Elite Files IND for Abuse-Resistant Technology for Narcotic Analgesics

Elite Pharmaceuticals' subsidiary, Elite Laboratories, has filed an investigational new drug (IND) application for an abuse-resistant oxycodone product utilizing Elite's proprietary abuse-resistant technology (ART).

Elite's ART incorporates an opioid antagonist and is designed to discourage and reduce abuse of narcotic analgesic medications by making the products more difficult to abuse when crushed, damaged or otherwise manipulated. No assurance can be given that the IND will be approved by the FDA.